Postmenopausal women using proton pump inhibitors (PPIs) long-term have an increased risk of hip fracture.
(PPIs) are a group of drugs whose main action is a pronounced and long-lasting reduction of gastric acid production. They are the most potent inhibitors of acid secretion available. These drugs are among the most widely sold drugs in the world, and are generally considered effective.
High dose or long-term use of PPIs carry a possible increased risk of bone fractures.
Clinically used proton pump inhibitors:·
- Omeprazole (brand names: Gasec, Losec, Prilosec, Zegerid, ocid, Lomac, Omepral, Omez,)
- Lansoprazole (/wiki/Lansoprazole) (brand names: Prevacid, Zoton, Monolitum, Inhibitol, Levant, Lupizole)
- Dexlansoprazole (brand name: Kapidex, Dexilant)
- Esomeprazole (brand names: Nexium, Esotrex, esso)
- Pantoprazole (brand names: Protonix, Somac, Pantoloc, Pantozol, Zurcal, Zentro, Pan, Controloc, Tecta)
- Rabeprazole (brand names: AcipHex, Pariet, Erraz, Zechin, Rabecid, Nzole-D, Rabeloc, Razo. Dorafem: combination with domperidone ).
- Ilaprazole (brand names: Ilapro, Lupilla, Adiza)
Compared to women who do not take PPIs, taking the agents regularly for two years increased the risk of hip fracture by 35%, and longer PPI use increased the risk.
The risk of hip fracture is 50% higher for PPI users who also smoked, compared to non PPI users.
Any risk of hip fracture returned to normal levels two years after patients ceased PPIs.
Like smoking, PPIs can inhibit the absorption of calcium.
You can know how much calcium you are eating each day by using the calcium calculator
Rheumatological Diseases Unit | www.cgem.ed.ac.uk